Prostate Cancer
Clarity and Nucleus RadioPharma Sign Master Services Agreement and Cu-67 SAR-bisPSMA Clinical Supply Agreement
November 11, 2024
Efficacy and Predictive Factors Analysis of Androgen Deprivation Plus Novel Hormone Therapy as Neoadjuvant Treatment for High-Risk Prostate Cancer.
November 11, 2024
Commercial prices and their influence on urology practices: Prostate cancer care among men with Medicare.
November 11, 2024
Plain language review: the safety of relugolix combination therapy for advanced prostate cancer.
November 11, 2024
Advanced Imaging for Localized Prostate Cancer.
November 11, 2024
A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer.
November 8, 2024
The impact of progression-directed therapy on survival in metastatic castration-refractory prostate cancer: MEDCARE phase 3 trial.
November 8, 2024
Multidimensional Healthcare Access Barriers to Prostate-Specific Antigen Testing: A Nation-Wide Panel Study in the United States From 2006 to 2020.
November 7, 2024
Cribriform Pattern Is a Predictive Factor of PSA Recurrence in Patients Receiving Radiotherapy After Prostatectomy.
November 7, 2024
PSA Kinetics Affect Prognosis in Patients With Castration-resistant Prostate Cancer Treated With Enzalutamide.
November 7, 2024